Literature DB >> 25565572

Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.

Shalini Shenoy1, Jaap J Boelens.   

Abstract

PURPOSE OF REVIEW: The role of hematopoietic cell transplantation in non-malignant disorders has increased exponentially with the recognition that multiple diseases can be controlled or cured if engrafted with donor-derived cells. This review provides an overview of advances made in alternative donor transplants for nonmalignant disorders. RECENT <br> FINDINGS: Stem cell sources, novel transplant methods, and sophisticated supportive care have simultaneously made giant strides toward improving the safety and efficacy of hematopoietic cell transplantation. This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cell sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant non-malignant disorders such as immune dysfunctions, marrow failure syndromes, metabolic disorders and hemoglobinopathies. Transplant complications such as graft rejection, infections, and graft versus host disease are better combated in this modern era of medicine, achieving better survival with decreased late effects. These aspects of transplant for non-malignant disorders are discussed. <br> SUMMARY: This review presents the progress made in the realm of hematopoietic cell transplantation for non-malignant disorders. It advocates the consideration of alternative donor transplants in the absence of human leukocyte antigen matched siblings when indicated by disease severity. The ultimate goal is to provide curative transplant options for more patients that can benefit from this intervention, prior to detrimental outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 25565572      PMCID: PMC4403859          DOI: 10.1097/MOP.0000000000000179

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  77 in total

1.  Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia.

Authors:  Renata Bizzetto; Carmen Bonfim; Vanderson Rocha; Gérard Socié; Franco Locatelli; Kawah Chan; Oscar Ramirez; Joel Stein; Samir Nabhan; Eliana Miranda; Jakob Passweg; Carmino Antonio de Souza; Eliane Gluckman
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.

Authors:  Roland Chu; Ruta Brazauskas; Fangyu Kan; Asad Bashey; Christopher Bredeson; Bruce Camitta; Kuang-Yueh Chiang; Haydar Frangoul; Robert Peter Gale; Adrian Gee; Biju George; Frederick D Goldman; Thomas G Gross; Vikas Gupta; Gregory A Hale; Luis Isola; Alvaro Urbano Ispizua; Hillard Lazarus; Judith Marsh; James Russell; Mitchell Sabloff; Edmund K Waller; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

3.  Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia.

Authors:  Hiroshi Yagasaki; Seiji Kojima; Hiromasa Yabe; Koji Kato; Hisato Kigasawa; Hisashi Sakamaki; Masahiro Tsuchida; Shunichi Kato; Takakazu Kawase; Yasuo Morishima; Yoshihisa Kodera
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

4.  Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach.

Authors:  Javid Gaziev; Marco Marziali; Antonella Isgrò; Pietro Sodani; Katia Paciaroni; Cristiano Gallucci; Marco Andreani; Manuela Testi; Gioia De Angelis; Cecilia Alfieri; Luisa Cardarelli; Michela Ribersani; Daniele Armiento; Guido Lucarelli
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

5.  Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Authors:  Matthew M Hsieh; Courtney D Fitzhugh; R Patrick Weitzel; Mary E Link; Wynona A Coles; Xiongce Zhao; Griffin P Rodgers; Jonathan D Powell; John F Tisdale
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

6.  Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.

Authors:  Lakshmanan Krishnamurti; Sandhya Kharbanda; Melinda A Biernacki; Wandi Zhang; K Scott Baker; John E Wagner; Catherine J Wu
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

7.  Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.

Authors:  Mitchell E Horwitz; Nelson J Chao; David A Rizzieri; Gwynn D Long; Keith M Sullivan; Cristina Gasparetto; John P Chute; Ashley Morris; Carolyn McDonald; Barbara Waters-Pick; Patrick Stiff; Steven Wease; Amnon Peled; David Snyder; Einat Galamidi Cohen; Hadas Shoham; Efrat Landau; Etty Friend; Iddo Peleg; Dorit Aschengrau; Dima Yackoubov; Joanne Kurtzberg; Tony Peled
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

8.  Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.

Authors:  Fiona L Wilkinson; Rebecca J Holley; Kia J Langford-Smith; Soumya Badrinath; Aiyin Liao; Alex Langford-Smith; Jonathan D Cooper; Simon A Jones; J Ed Wraith; Rob F Wynn; Catherine L R Merry; Brian W Bigger
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

9.  Enhanced generation of cord blood hematopoietic stem and progenitor cells by culture with StemRegenin1 and Delta1(Ext-IgG.).

Authors:  A Dahlberg; C Brashem-Stein; C Delaney; I D Bernstein
Journal:  Leukemia       Date:  2014-06-06       Impact factor: 11.528

10.  Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Authors:  J C Marsh; R M Pearce; M B C Koh; Z Lim; A Pagliuca; G J Mufti; J Perry; J A Snowden; A J Vora; R T Wynn; N Russell; B Gibson; M Gilleece; D Milligan; P Veys; S Samarasinghe; M McMullin; K Kirkland; G Cook
Journal:  Bone Marrow Transplant       Date:  2013-08-05       Impact factor: 5.483

View more
  6 in total

1.  In vivo engineering of bone tissues with hematopoietic functions and mixed chimerism.

Authors:  Yu-Ru Shih; Heemin Kang; Vikram Rao; Yu-Jui Chiu; Seong Keun Kwon; Shyni Varghese
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

Review 2.  Placenta-based therapies for the treatment of epidermolysis bullosa.

Authors:  Christopher Nevala-Plagemann; Catherine Lee; Jakub Tolar
Journal:  Cytotherapy       Date:  2015-03-18       Impact factor: 5.414

3.  Decision Making in Adrenoleukodystrophy: When Is a Good Outcome Really a Good Outcome?

Authors:  Keith Van Haren; Marc Engelen
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

4.  Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation.

Authors:  Wing Hing Wong; Sima Bhatt; Kathryn Trinkaus; Iskra Pusic; Kevin Elliott; Nitin Mahajan; Fei Wan; Galen E Switzer; Dennis L Confer; John DiPersio; Michael A Pulsipher; Nirali N Shah; Jennifer Sees; Amelia Bystry; Jamie R Blundell; Bronwen E Shaw; Todd E Druley
Journal:  Sci Transl Med       Date:  2020-01-15       Impact factor: 17.956

5.  Ovarian tissue cryopreservation in young females through the Oncofertility Consortium's National Physicians Cooperative.

Authors:  Austin G Armstrong; Bruce F Kimler; Brigid M Smith; Teresa K Woodruff; Mary Ellen Pavone; Francesca E Duncan
Journal:  Future Oncol       Date:  2018-01-18       Impact factor: 3.404

6.  Haploidentical Hematopoietic Cell Transplantation Using Post-transplant Cyclophosphamide for Children with Non-malignant Diseases.

Authors:  Hasan Hashem; Rula Najjar; Mayada Abu-Shanap; Eman Khattab; Rawad Rihani; Abdelghani Tbakhi; Iyad Sultan
Journal:  J Clin Immunol       Date:  2021-08-06       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.